Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA psychiatry"
DOI: 10.1001/jamapsychiatry.2021.3997
Abstract: Importance Serotonin reuptake inhibitors (SRIs) are the only medications approved for obsessive-compulsive disorder (OCD), yet most patients taking SRIs exhibit significant symptoms. Adding exposure/response prevention (EX/RP) therapy improves symptoms, but it is unknown whether patients… read more here.
Keywords: trial; group; continuation group; taper group ... See more keywords